21st Sep 2015 06:33
LONDON (Alliance News) - Shire PLC said Monday it has received approval from the European Commission for Intuniv for the treatment of attention deficit hyperactivity disorder in children and adolescents from 6 to 17 years old for whom stimulants are not suitable, not tolerated or ineffective.
"The approval of INTUNIV marks a significant advance in the treatment of ADHD in children and adolescents in Europe. Previously, physicians had only one licensed non-stimulant option for these patients," said Senior Vice President of Shire's Neuroscience Business Unit Perry Sternberg in a statement.
"The importance of simply providing physicians with the ability to choose the non-stimulant option that may best suit the needs of their patients should not be overlooked, considering the complexities and different manifestations of the disorder in children and adolescents," Sternberg added.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Shire